By the Numbers: Our Response to COVID-19

November 11, 2020

We are honored to support a resilient research community during the COVID-19 pandemic. See the data points below, watch the video, and download our info sheet to find out how Advarra helps keep research moving forward.

Advarra’s COVID-19 Response by the Numbers

IRB and IBC Support

  • 100% Operation Warp Speed Vaccine Trials supported by Advarra’s IRB and IBC
  • IRB reviewed 429 COVID-19 protocols across over 2,500 sites
  • IBC reviewed 76 COVID-19 submissions
  • First COVID-19 protocol submission received: 2/11/20
  • Reviews conducted for Phase I-IV plus observational data and collection research
  • Free transfers of IRB oversight to keep research moving despite pandemic restrictions: 116 studies, over 500 sites
  • IRB average turnaround from submission to review: 1-2 business days
  • IBC average turnaround from submission to review: 4-5 business days

Research Administration Support

  • Remote audits conducted worldwide: 125 across 5 continents
  • Staff augmentation: 20+ experts deployed to support organizations, some in response to layoffs & furloughs
  • COVID study calendars built for OnCore customers: 179
  • Average study calendar turnaround time: 1 business day
  • Advarra eRegulatory management system: supported 3,187 users; 239,435 documents; 84,752 signatures; 1,100 review sessions; 1,804 protocols

Free Educational Resources

  • COVID-related webinars and virtual events: 9 and reached 15,000+ research professionals
  • eLearning tool downloads: 669
  • COVID-centric blog posts: 21

Ask Advarra

Launched March 16, 2020, Ask The Experts was the first free source for direct information on IRB, IBC, and regulatory concerns related to COVID-19 and research.

  • Target time from question submission to response: 24 hours
  • Questions answered same day as submission: 90%
  • Questions answered: 655 and counting

Coronavirus Guidance

Our Coronavirus Guidance webpages provide timely information and explanations about pandemic-related research changes, regulatory guidance updates, and other critical resources. Popular questions from Ask Advarra are posted to the Coronavirus Guidance so that all may benefit.

  • Research professionals helped: over 20,500
  • Subscribers to weekly email updates: 425
  • Frequency of updates: weekly
  • Versions of Advarra’s Coronavirus Guidance Page: 22
  • Email updates sent: Approximately 7,000
  • Topics covered: 30
  • Worldwide regulatory and other resources cited: 16
    • ­­­FDA
    • Health Canada
    • AEMPS
    • HMA
    • HHS
    • OCR
    • MHRA
    • NCI
    • VA
    • Agency of Medicines
    • EMA
    • EC
    • PRIM&R
    • Agenzia Italiana del Farmaco
    • CITI
    • BBK

Data accurate as of October 2020.

Back to Resources